Open AccessHPV genotype distribution in older Danish women undergoing surgery due to cervical cancer
Author(s) -
Hammer Anne,
Mejlgaard Else,
Gravitt Patti,
Høgdall Estrid,
Christiansen Pernille,
Steiniche Torben,
Blaakær Jan
Publication year - 2015
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/aogs.12731
Subject(s) - medicine , cervical cancer , danish , genotyping , genotype , human papillomavirus , gynecology , hpv infection , hpv vaccines , university hospital , disease , cancer , obstetrics , philosophy , linguistics , biochemistry , chemistry , gene
Abstract Introduction The prevalence of human papillomavirus ( HPV )16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer. Material and methods In this cross‐sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990–2012) and Copenhagen University Hospital Herlev, Denmark (2007–2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO Li PA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age‐specific prevalence of high‐risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine. Results Of 121 cases of cervical cancer included in this study, 113 were HPV ‐positive (93.4%). Although HPV 16 and 18 were the most common genotypes overall, the prevalence of HPV 16/18 decreased significantly from 78.1% in women aged 55–59 years to 45.5% in women aged 75 or older ( p < 0.001), whereas the prevalence of other HPV types and HPV ‐negative cases tended to increase with age ( p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90% until the age of 75 years and then dropped to 63%. Conclusion In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age‐range compared with the reduced type‐spectrum vaccines.